StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Nasonex by Quarter

Nasonex (mometasone, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Nasonex: $2M in Q1 2021, down 66.7% from a year earlier. No newer figure appears in the documents we track.

Latest, Q1 2021
2
Period ended Mar 31, 2021
Change on a year earlier
-66.7%
6 in Q1 2020
History
18 quarters
Since Q4 2016
Sources
14
Documents cited below

Where the Q1 2021 figure comes from

“|| Nasonex | 43 | 71 | -39 | 2 | 6 | -65 | 41 | 65 | -37”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNasonex (mometasone, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 20212-66.7%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 2020-5-171.4%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 20205+25.0%Form 10-Q (filed 2020-11-05) ↗
Q2 2020Jun 30, 20204-500.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 20206-700.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 20197-53.3%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 20194-42.9%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 2019-1-114.3%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 2019-1-200.0%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 201815-59.5%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 20187-130.4%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 20187-66.7%Form 10-Q (filed 2019-08-06) ↗
Q1 2018Mar 31, 20181-94.4%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 201737+60.9%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 2017-23–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 201721–Form 10-Q (filed 2018-08-07) ↗

Breakdown

What makes up nasonex

Cite this data

StockData. (2026). Merck Nasonex ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-nasonex-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.